ライフサイエンスコーパス: plasma clearance

1 Primary outcome was measured GFR (iohexol plasma clearance).

2 ble, 18.4 h oral t(1/2), and 0.19 L/(h x kg) plasma clearance).

3 docytosis of circulating LDL, increasing its plasma clearance.

4 ral dosing, but exposure was limited by high plasma clearance.

5 adrenaline concentrations because of reduced plasma clearance.

6 GC 945 to KB tumor-bearing mice showed rapid plasma clearance (0.021 L/h) and tissue distribution.

7 half-life of disposition 69.7 +/- 39.7 hrs, plasma clearance 2.39 +/- 1.32 mL/hr/kg, and volume of d

8 he liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide upt

9 e drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing expos

10 ient) were 10.8% and 0.88, respectively, for plasma clearance and 15.3% and 0.77, respectively, for f

11 RSHZ19 had low plasma clearance and a half-life of approximately 23 day

12 higher plasma free fraction, and (c) faster plasma clearance and brain uptake kinetics, enabling mea

13 the C15 and C18 analogues displaying delayed plasma clearance and enhanced tumor uptake and retention

14 A, which in experimental models has a slower plasma clearance and greater fibrin specificity and is 8

15 receptor-related protein function, decreased plasma clearance and hepatic uptake of (131)I-apoB-48 LD

16 ptor class B (SR-BI) failed to normalize the plasma clearance and liver uptake of [(3)H]CE from LCAT-

17 roperties in the rat and dog with respect to plasma clearance and oral bioavailability and is a poten

18 Although the plasma clearance and the rate of renal excretion of the

19 To determine the plasma clearance and tissue distribution in mice of the

20 f eliminating the MR on MR- and MPR-mediated plasma clearance and tissue distribution of infused phos

21 bind the replaced glycoprotein, increase its plasma clearance, and inhibit its activity, preventing s

22 umor model simulating the interstitial flow, plasma clearance, and transport of the drug within the t

23 of them has a good correlation with UV/P or plasma clearance at this level of renal function.

24 ts provided excellent renal images, with the plasma clearance averaging 228 mL/min for (99m)Tc(CO)(3)

25 duced cocaine burden in tissues, accelerated plasma clearance by 20-fold, and prevented cocaine-induc

26 rformed to quantify manganese and gadolinium plasma clearance by using inductively coupled plasma mas

27 mple at 45 min was found to be 23, using the plasma clearance calculated from a multi-sample clearanc

28 51)Cr-ethylenediaminetetraacetic acid (EDTA) plasma clearance counting but is time-consuming and requ

29 (99m)Tc-Diethylenetriaminepentaacetic acid plasma clearance curves from 79 subjects were analyzed.

30 We evaluated this approach for interpreting plasma clearance curves with the goal of reducing curve-

31 by applying a three-compartment model to the plasma clearance data of intravenously injected [(14)C]i

32 Dose-dependent changes in plasma clearance did not occur.

33 ts show that these three compounds exhibit a plasma clearance equivalent to iothalamate (a commonly c

34 We estimated methotrexate plasma clearance for 1279 patients with ALL treated with

35 n cultured cells and dramatically slowed its plasma clearance from a t(1/2) of <10 min to 18 h.

36 Mean plasma clearance, half-life, and steady-state volume of

37 Mean plasma clearance in humans was 9 +/- 3 mL/min/kg, and th

38 ng polyacrylamide gel electrophoresis and by plasma clearance in mice.

39 Plasma clearances in BALB/c mice are similar among the f

40 Plasma clearance (in liters per hour) and free fraction

41 based formulas with a gold standard (iohexol plasma clearance) in 193 renal transplant recipients usi

42 ; measurements of (14)C-ACPC and (67)Ga-DTPA plasma clearance (K(1)), (14)C-ACPC transport ( partial

43 hods of measuring whole-skeleton (99m)Tc-MDP plasma clearance (K(bone)) in 12 osteoporotic postmenopa

44 Iohexol plasma clearance measurement as gold standard.

45 n volunteers followed by sequential imaging, plasma clearance measurements and timed urine collection

46 Each study included a UV/P, plasma clearance method (three-sample) and single-sample

47 GFR measured by nonradiolabeled iothalamate plasma clearance (mGFR) in 72 subjects with cirrhosis.

48 uterium-labeled steroid hormones as tracers; plasma clearance of 100 mg of hydrocortisone; levels of

49 se complexes (alpha 2M*) also diminished the plasma clearance of 125I-factor Xa in a dose-dependent f

50 ng activity displayed dramatically prolonged plasma clearance of 125I-factor Xa.

51 TNK-TPA demonstrated a plasma clearance of 151 +/- 55 mL/min and a half-life of

52 In normal rats, the plasma clearance of 18F-PFH was 4.11+/-1.09 mL/min/100 g

53 The plasma clearance of 18F-PFH was determined using a singl

54 Finally, the plasma clearance of 2d, 2h, and 2j remained unchanged up

55 4 years' follow-up we estimated GFR from the plasma clearance of 51Cr-labelled edetic acid (EDTA), an

56 Compared with labeled antibody, plasma clearance of 99mTc was faster with labeled EPI-HN

57 CETP normalized both the plasma clearance of [(3)H]cholesteryl esters ([(3)H]CE)

58 s (OATPs) mediate the liver uptake and hence plasma clearance of a broad range of drugs.

59 apoA-II transgenic mice exhibited a delay in plasma clearance of a glucose bolus.

60 Plasma clearance of active TPA was faster than clearance

61 ound to alpha2M or alpha2M-MA did not affect plasma clearance of alpha2M/alpha2M-MA.

62 en together, these data showed that impaired plasma clearance of apoE2-containing, triglyceride-rich

63 in the liver responsible for the binding and plasma clearance of apolipoprotein E-containing lipoprot

64 r both before and after I/R and improved the plasma clearance of bile acid and biliary outputs of bil

65 Genetically eliminating the MR slowed plasma clearance of both P- and NP-GUS and enhanced the

66 ignificant correlations between CrCl and the plasma clearance of both total topotecan [Spearman's cor

67 Recent studies have demonstrated that plasma clearance of cortisol is markedly reduced during

68 d by urinary clearance of inulin (n=488) and plasma clearance of Cr-EDTA (n=337).

69 The impact of plasma clearance of dexamethasone and anti-asparaginase

70 imum observed plasma concentration and total plasma clearance of ET-743 (mean +/- standard deviation)

71 ethods for GFR measurement using urinary and plasma clearance of exogenous filtration markers and foc

72 Pharmacokinetic evaluation of the plasma clearance of GBCA is required for all new agents

73 Plasma clearance of HDL particles and HDL-associated cho

74 Although the plasma clearance of HDL-CE was not significantly altered

75 Importantly, the plasma clearance of hFVIII was significantly decreased i

76 synthesized VLDL normally but showed reduced plasma clearance of human VLDL and a corresponding reduc

77 addition, coinjection of free OX26 saturated plasma clearance of immunoliposomes.

78 ocus on urinary clearance of iothalamate and plasma clearance of iohexol compared with inulin clearan

79 filtration rate (determined by measuring the plasma clearance of iohexol) between the baseline value

80 change from baseline in GFR, measured by the plasma clearance of iohexol.

81 erious disorder caused by very low or absent plasma clearance of LDL, substantially raised LDL choles

82 PS, whereas SR-BI-null mice showed decreased plasma clearance of LPS into the liver and hepatocytes c

83 We suggest plasma clearance of nonradioactive markers be more widel

84 The plasma clearance of PEG-rHDL was estimated after injecti

85 ions as a liver receptor responsible for the plasma clearance of SECs.

86 GFR, measured as the plasma clearance of the endogenous marker iohexol, to co

87 Plasma clearance of the major radiolabeled metabolite ([

88 Mean systemic plasma clearance of total topotecan was significantly re

89 There was no difference in the plasma clearances of (99m)Tc(CO)(3)(NTA) and (131)I-OIH,

90 There was no difference in the plasma clearances of (99m)Tc(CO)3(NTA) and (131)I-OIH (1

91 ntrast to the situation observed in baboons, plasma clearances of both compounds were similar in huma

92 The plasma clearances of Na(2)[(99m)Tc(CO)(3)(NTA)] and (131

93 area under the curve (0-last) and decreased plasma clearance over compound I and efavirenz, the stan

94 and desialylated pFn (aFn) displayed a rapid plasma clearance (P < .001) with greater than 50% of bot

95 ution of ADC, independent of payload dose or plasma clearance, plays a major role in ADC efficacy.Sig

96 Pemetrexed plasma clearance positively correlated with GFR (r2 = 0.

97 amine sulfoconjugated to the respective free plasma clearances (r2 = .30, p < .01, and r2 = 0.29, p <

98 the natural logarithm of the respective free plasma clearances (r2 = 0.58, p < .001, and r2 = 0.39, p

99 lus and the Thiele modulus are ratios of the plasma clearance rate and antibody catabolism, respectiv

100 On a time scale of minutes, we determine the plasma clearance rate in the wild-type mouse, using time

101 was metabolically stable and displayed a low plasma clearance rate.

102 The (99m)Tc-MAEC complex/(131)I-OIH plasma clearance ratio in humans ranged from 45% (anti-(

103 Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, tho

104 A total of 12 plasma clearance studies for AA and urea, consisting of

105 ion within a tumor including dose, affinity, plasma clearance, target expression, internalization, pe

106 AF-L displayed a quicker plasma clearance than CL, and 25.4%, 2.7%, and 1.2% of t

107 Plasma clearance, the molecular composition of radioacti

108 es were about 21.1 and 3.4 times slower than plasma clearance times for nalmefene and naloxone, respe

109 analysis) were used to evaluate the fluoride plasma clearance to bone mineral (K(i)).

110 The plasma clearance, total volume of distribution, and term

111 ts, which was commensurate with the observed plasma clearance values upon intravenous administration.

112 result in a 2-5-fold increase in calculated plasma clearance values when the excipient interferes wi

113 netic experiments, four trioxolanes had high plasma clearance values, suggesting a potential metaboli

114 curve increased linearly with dose, and mean plasma clearance was 1.86 mL/kg/min (range, 1.21 to 2.41

115 controls -(5.3 +/- 1.7) x 10(-3) s(-1), and plasma clearance was 2.6-fold higher in BCC than control

116 Plasma clearance was 29 +/- 1 L/h, and plasma free fract

117 The mean +/- standard deviation IRN plasma clearance was 374 +/- 148 mL/min/m2, with median

118 The median flavopiridol plasma clearance was 8.0 L/h/m2 (range, 2.6 to 17.1 L/h/

119 The mean total body plasma clearance was 95.7 +/- 30.8 m/min and the harmoni

120 Plasma clearance was FHBG > FHPG >> FIAU.

121 ter iv ddI administration, only the maternal plasma clearance was found to be significantly increased

122 ined in a biexponential manner, and systemic plasma clearance was high relative to liver blood flow.

123 elation of the single-sample method with the plasma clearance was higher than with UV/P.

124 Plasma clearance was rapid, with liver and kidneys repre

125 Plasma clearances were determined from 10 blood samples

126 Plasma clearances were determined from 8 blood samples o

127 The 90Y/111In-DOTA-biotin had a rapid plasma clearance, which was biphasic with <10% residual

128 examethasone drug conjugate exhibited a fast plasma clearance, with a half-life of approximately 5-8